Skip to content

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$509M+9.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.19M-7.6%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$626K-2.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$463K-25.6%
CG Oncology logo
CG OncologyCGON
$841K+3,404%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$4.32M-8.8%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's D&A?
Celcuity (CELC) reported D&A of $47K in Q1 2026.
How has Celcuity's D&A changed year-over-year?
Celcuity's D&A increased by 27.0% year-over-year, from $37K to $47K.
What is the long-term trend for Celcuity's D&A?
Over 4 years (2021 to 2025), Celcuity's D&A has grown at a -13.9% compound annual growth rate (CAGR), from $303.24K to $167K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.